Int J Med Sci 2021; 18(2):406-418. doi:10.7150/ijms.47706 This issue

Review

DCs-based therapies: potential strategies in severe SARS-CoV-2 infection

Jian Han1,2,3#, Jiazhi Sun3✉, Guixin Zhang1,2✉, Hailong Chen1,2✉

1. General Surgery Department, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
2. Institute of Integrative Medicine of Dalian Medical University, Dalian 116044, China.
3. Department of Pharmaceutical Sciences USF Health, Taneja College of Pharmacy University of South Florida, Tampa, FL, USA.
#First author.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Han J, Sun J, Zhang G, Chen H. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection. Int J Med Sci 2021; 18(2):406-418. doi:10.7150/ijms.47706. Available from https://www.medsci.org/v18p0406.htm

File import instruction

Abstract

Pneumonia caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is spreading globally. There have been strenuous efforts to reveal the mechanisms that the host defends itself against invasion by this virus. The immune system could play a crucial role in virus infection. Dendritic cell as sentinel of the immune system plays an irreplaceable role. Dendritic cells-based therapeutic approach may be a potential strategy for SARS-CoV-2 infection. In this review, the characteristics of coronavirus are described briefly. We focus on the essential functions of dendritic cell in severe SARS-CoV-2 infection. Basis of treatment based dendritic cells to combat coronavirus infections is summarized. Finally, we propose that the combination of DCs based vaccine and other therapy is worth further study.

Keywords: dendritic cells (DCs) vaccine, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, immunotherapy, immune system response, therapeutic vaccine